Assessing survival in non-small cell lung cancer brain metastases after stereotactic radiosurgery: before and after the start of the targetable mutation era

Cole, Kyril L.; Earl, Emma R.; Findlay, Matthew C.; Sherrod, Brandon A.; Tenhoeve, Samuel A.; Kunzman, Jessica; Cannon, Donald M.; Akerley, Wallace; Burt, Lindsay; Seifert, Seth B.; Goldman, Matthew; Jensen, Randy L.

doi:10.1007/s11060-024-04749-5

J Neurooncol

2024

DOI: 10.1007/s11060-024-04749-5

|View full text |Cite

Assessing survival in non-small cell lung cancer brain metastases after stereotactic radiosurgery: before and after the start of the targetable mutation era

Kyril L. Cole,

Emma R. Earl,

Matthew C. Findlay

et al.

Help me understand this report

View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Return to work in younger patients with brain metastases who survived for 2 years or more

Nieder,

Aanes,

Stanisavljevic

et al. 2024

J Neurooncol

View full text Add to dashboard Cite

Purpose The study’s purpose was to analyze return to work and other long-term outcomes in younger patients with newly diagnosed brain metastases, treated before they reached legal retirement age, i.e. younger than 65 years. Methods We included patients who survived greater than 2 years after their first treatment, regardless of approach (systemic therapy, neurosurgical resection, whole-brain or stereotactic radiotherapy). The primary endpoint was the proportion of patients who worked 2 years after their initial treatment for brain metastases. Outcomes beyond the 2-year cut-off were also abstracted from comprehensive electronic health records, throughout the follow-up period. Results Of 455 patients who received active therapy for brain metastases, 62 (14%) survived for > 2 years. Twenty-eight were younger than 65 years. The actuarial median survival was 81 months and the 5-year survival rate 53%. For patients alive after 5 years, the 10-year survival rate was 54%. At diagnosis, 25% of patients (7 of 28) were permanently incapacitated for work/retired. Of the remaining 21 patients, 33% did work 2 years later. However, several of these patients went on to receive disability pension afterwards. Eventually, 19% continued working in the longer run. Younger age, absence of extracranial metastases, presence of a single brain metastasis, and Karnofsky performance status 90–100 were common features of patients who worked after 2 years. Conclusion Long-term survival was achieved after vastly different therapeutic approaches, regarding both upfront and sequential management. Many patients required three or more lines of brain-directed treatment. Few patients continued working in the longer run.

show abstract

Return to work in younger patients with brain metastases who survived for 2 years or more

Nieder,

Aanes,

Stanisavljevic

et al. 2024

J Neurooncol

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Assessing survival in non-small cell lung cancer brain metastases after stereotactic radiosurgery: before and after the start of the targetable mutation era

Cited by 1 publication

References 34 publications

Return to work in younger patients with brain metastases who survived for 2 years or more

Return to work in younger patients with brain metastases who survived for 2 years or more

Contact Info

Product

Resources

About